Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Celyad

Nasdaq:CYAD
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CYAD
Nasdaq
€93M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
  • Celyad has significant price volatility in the past 3 months.
CYAD Share Price and Events
7 Day Returns
33.6%
NasdaqGM:CYAD
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-60.4%
NasdaqGM:CYAD
0%
US Biotechs
-11.5%
US Market
CYAD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celyad (CYAD) 33.6% -9.9% -21.6% -60.4% -69.2% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • CYAD underperformed the Biotechs industry which returned 0% over the past year.
  • CYAD underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
CYAD
Industry
5yr Volatility vs Market
Related Companies

CYAD Value

 Is Celyad undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Celyad. This is due to cash flow or dividend data being unavailable. The share price is $8.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celyad's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celyad's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CYAD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-2.29
ENXTBR:CYAD Share Price ** ENXTBR (2020-03-27) in EUR €6.69
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celyad.

NasdaqGM:CYAD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:CYAD Share Price ÷ EPS (both in EUR)

= 6.69 ÷ -2.29

-2.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is loss making, we can't compare its value to the US Biotechs industry average.
  • Celyad is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Celyad's expected growth come at a high price?
Raw Data
NasdaqGM:CYAD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-15.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Celyad, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Celyad's assets?
Raw Data
NasdaqGM:CYAD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.49
ENXTBR:CYAD Share Price * ENXTBR (2020-03-27) in EUR €6.69
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:CYAD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:CYAD Share Price ÷ Book Value per Share (both in EUR)

= 6.69 ÷ 3.49

1.92x

* Primary Listing of Celyad.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Celyad's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celyad has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CYAD Future Performance

 How is Celyad expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-15.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celyad expected to grow at an attractive rate?
  • Unable to compare Celyad's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Celyad's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Celyad's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CYAD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CYAD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -15.1%
NasdaqGM:CYAD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 36.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CYAD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CYAD Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 44 1
2023-12-31 17 1
2022-12-31 0 -46 1
2021-12-31 53 -37 -39 6
2020-12-31 5 -30 -34 5
2020-03-28
NasdaqGM:CYAD Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -28 -29
2019-09-30 0 -29 -32
2019-06-30 1 -29 -35
2019-03-31 2 -28 -36
2018-12-31 3 -27 -37
2018-09-30 3 -49
2018-06-30 3 -44 -60
2018-03-31 3 -44 -58
2017-12-31 4 -44 -56
2017-09-30 9 -39
2017-06-30 12 -18 -21
2017-03-31 10 -22 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celyad is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Celyad's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CYAD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Celyad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CYAD Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 -3.38 -3.38 -3.38 1.00
2020-12-31 -3.38 -3.38 -3.38 1.00
2020-03-28
NasdaqGM:CYAD Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -2.29
2019-09-30 -2.60
2019-06-30 -2.92
2019-03-31 -3.13
2018-12-31 -3.36
2018-09-30 -4.62
2018-06-30 -6.01
2018-03-31 -5.94
2017-12-31 -5.86
2017-09-30 -4.07
2017-06-30 -2.24
2017-03-31 -2.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Celyad will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Celyad's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celyad has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CYAD Past Performance

  How has Celyad performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celyad's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celyad does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Celyad's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Celyad's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Celyad's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celyad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CYAD Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.01 -28.63 9.07 25.20
2019-09-30 0.30 -31.78 9.25 25.17
2019-06-30 0.60 -34.93 9.44 25.15
2019-03-31 1.86 -36.18 9.91 24.36
2018-12-31 3.12 -37.43 10.39 23.58
2018-09-30 2.83 -48.93 10.46 23.24
2018-06-30 2.55 -60.44 10.52 22.90
2018-03-31 3.05 -58.42 9.92 22.90
2017-12-31 3.54 -56.40 9.31 22.91
2017-09-30 9.25 -38.75 9.28 23.14
2017-06-30 11.99 -21.10 9.25 23.38
2017-03-31 10.26 -22.35 9.50 25.53
2016-12-31 10.01 -23.61 9.74 27.68
2016-09-30 4.28 -27.15 9.04 27.17
2016-06-30 0.04 -30.70 8.34 26.67
2016-03-31 0.02 -29.91 7.79 24.72
2015-12-31 0.00 -29.11 7.23 22.77
2015-09-30 0.07 -27.26 6.93 21.82
2015-06-30 0.15 -25.41 6.62 20.88
2015-03-31 0.15 -20.93 5.82 18.37
2014-12-31 0.15 -16.45 5.02 15.87
2014-09-30 0.07 -15.45 5.06 15.18
2014-06-30 -14.44 5.10 14.49
2014-03-31 -14.95 4.51 11.77
2013-12-31 -14.49 3.97 9.05
2013-09-30 0.03 -12.77 2.38 2.28
2013-06-30 0.05 -13.20 1.77 2.41
2013-03-31 0.05 -11.90 1.85 2.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Celyad has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Celyad has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Celyad improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Celyad's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celyad has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CYAD Health

 How is Celyad's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celyad's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celyad is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celyad's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Celyad's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 187.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celyad Company Filings, last reported 2 months ago.

NasdaqGM:CYAD Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 45.62 0.23 39.34
2019-09-30 45.62 0.23 39.34
2019-06-30 40.92 0.37 33.67
2019-03-31 40.92 0.37 33.67
2018-12-31 55.59 0.51 49.74
2018-09-30 55.59 0.51 49.74
2018-06-30 72.68 0.65 63.23
2018-03-31 72.68 0.65 63.23
2017-12-31 47.54 0.54 33.91
2017-09-30 47.54 0.54 33.91
2017-06-30 77.25 0.00 68.84
2017-03-31 77.25 0.00 68.84
2016-12-31 90.89 0.74 82.59
2016-09-30 90.89 0.74 82.59
2016-06-30 96.63 0.00 86.03
2016-03-31 96.63 0.00 86.03
2015-12-31 111.47 0.00 107.51
2015-09-30 111.47 0.00 107.51
2015-06-30 124.89 0.00 123.79
2015-03-31 124.89 0.00 123.79
2014-12-31 26.68 0.00 30.30
2014-09-30 26.68 0.00 30.30
2014-06-30 35.68 0.00 40.07
2014-03-31 35.68 0.00 40.07
2013-12-31 16.90 0.00 22.06
2013-09-30 16.90 0.00 22.06
2013-06-30 -1.12 0.00 3.94
2013-03-31 -4.44 0.00 0.11
  • Celyad's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Celyad has sufficient cash runway for 1.4 years based on current free cash flow.
  • Celyad has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 12.6% each year.
X
Financial health checks
We assess Celyad's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celyad has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CYAD Dividends

 What is Celyad's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celyad dividends.
If you bought $2,000 of Celyad shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celyad's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celyad's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CYAD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CYAD Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celyad has not reported any payouts.
  • Unable to verify if Celyad's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celyad's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celyad has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Celyad's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celyad afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celyad has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CYAD Management

 What is the CEO of Celyad's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Filippo Petti
AGE 47
TENURE AS CEO 0.9 years
CEO Bio

Mr. Filippo Joseph Petti serves as Director at Celyad SA since November 2019. He has been the Chief Executive Officer and Chief Financial Officer of Celyad SA since April 1, 2019. Mr. Petti served as the Chief Financial Officer at Celyad SA since September 2018 until April 1, 2019. Mr. Petti served as Chief Financial Officer and Investor Relations at Celyad SA since September 03, 2018 until September 2018. He currently serves as vice president of healthcare investment banking at Wells Fargo Securities. Before joining Wells Fargo Securities, he was vice president of healthcare investment banking at William Blair & Company. Prior to his roles in investment banking, Mr. Petti worked in equity research both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. before transitioning to corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University.

CEO Compensation
  • Insufficient data for Filippo to compare compensation growth.
  • Insufficient data for Filippo to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Celyad management team in years:

3.3
Average Tenure
51
Average Age
  • The tenure for the Celyad management team is about average.
Management Team

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€73K
AGE
63

Filippo Petti

TITLE
CEO, CFO & Director
AGE
47
TENURE
0.9 yrs

Jean-Pierre Latere

TITLE
Chief Operating Officer
AGE
44
TENURE
3.2 yrs

Nicolas Van Hoecke

TITLE
Director of Investor Relations & Communications
TENURE
1.5 yrs

Philippe Dechamps

TITLE
Chief Legal Officer
AGE
49
TENURE
3.5 yrs

Philippe Nobels

TITLE
Global Head of Human Resources
AGE
53
TENURE
3.4 yrs

Stephen Rubino

TITLE
Chief Business Officer

Frédéric Lehmann

TITLE
Vice President of Clinical Development & Medical Affairs
AGE
55
TENURE
3.7 yrs
Board of Directors Tenure

Average tenure and age of the Celyad board of directors in years:

3.9
Average Tenure
56
Average Age
  • The tenure for the Celyad board of directors is about average.
Board of Directors

Filippo Petti

TITLE
CEO, CFO & Director
AGE
47
TENURE
0.3 yrs

Serge Goblet

TITLE
Non-Executive Director
COMPENSATION
€38K
AGE
61
TENURE
12.2 yrs

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€73K
AGE
63
TENURE
13.2 yrs

Chris Buyse

TITLE
Independent Director
COMPENSATION
€60K
AGE
55
TENURE
12.2 yrs

Rudy DeKeyser

TITLE
Independent Director
COMPENSATION
€73K
AGE
57
TENURE
13.2 yrs

Hinrich Abken

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Scott Antonia

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Marco Davila

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Marc Ernstoff

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Stéphane Dépil

TITLE
Member of Scientific Advisory Board
AGE
44
TENURE
3.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Celyad's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celyad has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CYAD News

Simply Wall St News

Why I Sold Celyad SA (NASDAQ:CYAD)

Whether a company has a good future, in terms of its business operation and financial health, is an important question to address. … A major red flag for CYAD is that its cash generated from its business is less than its outgoing cash expenses. … One reason I do like CYAD as a business is its low level of fixed assets on its balance sheet (4.24% of total assets).

Simply Wall St -

Where Celyad SA's (NASDAQ:CYAD) Earnings Growth Stands Against Its Industry

Understanding how Celyad SA (NASDAQ:CYAD) is performing as a company requires looking at more than just a years' earnings. … Today I will run you through a basic sense check to gain perspective on how Celyad is doing by comparing its latest earnings with its long-term trend as well as the performance of its biotechs industry peers. … Scanning growth from a sector-level, the US biotechs industry has been growing its average earnings by double-digit 22.93% in the past twelve months, and 19.64% over the past half a decade.

Simply Wall St -

CYAD Company Info

Description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. The company’s lead drug product candidate, CYAD-01 (CAR-T-NKG2D), an autologous chimeric antigen receptor that is in Phase I clinical trials, which expresses the NKG2D receptor from natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells for the treatment of patients with relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an investigational, non-gene edited allogeneic CAR-T therapy that is in Phase I trials, which co-expresses the NKG2D receptor of CYAD-01 and the inhibitory peptide Tcell receptor inhibiting molecule; and preclinical development CAR-T product candidates, such as CYAD-02 and CYAD-03 for the treatment of hematological malignancies and solid tumors. In addition, the company’s short hairpin RNA-based allogeneic CAR-T candidates comprise CYAD-211, a B-cell maturation antigen targeting CAR-T candidate for the treatment of multiple myeloma; CYAD-221, a CD19 targeting CAR-T candidate for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad SA has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; a collaboration with Be The Match BioTherapies for the development of allogeneic CAR-T therapies; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Details
Name: Celyad SA
CYAD
Exchange: NasdaqGM
Founded: 2004
€103,419,759
13,942,344
Website: http://www.celyad.com
Address: Celyad SA
Axis Business Park,
Rue Edouard Belin 2,
Mont-Saint-Guibert,
Walloon Brabant, 1435,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR CYAD Ordinary Shares Euronext Brussels BE EUR 04. Jul 2013
OTCPK CLYY.F Ordinary Shares Pink Sheets LLC US USD 04. Jul 2013
DB 1C0 Ordinary Shares Deutsche Boerse AG DE EUR 04. Jul 2013
LSE 0QFK Ordinary Shares London Stock Exchange GB EUR 04. Jul 2013
BATS-CHIXE CYADB Ordinary Shares BATS 'Chi-X Europe' GB EUR 04. Jul 2013
NasdaqGM CYAD ADR Nasdaq Global Market US USD 22. Jun 2015
Number of employees
Current staff
Staff numbers
94
Celyad employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:38
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.